Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

被引：1

作者：

Morschhauser, Franck ^{[1
]}

Flinn, Ian ^{[2
]}

Advani, Ranjana H. ^{[3
]}

Diefenbach, Catherine S. ^{[4
]}

Kolibaba, Kathryn ^{[5
]}

Press, Oliver W. ^{[6
]}

Sehn, Laurie H. ^{[7
]}

Chen, Andy I. ^{[8
]}

Salles, Gilles ^{[9
]}

Tilly, Herve ^{[10
]}

Cheson, Bruce D. ^{[11
]}

Assouline, Sarit ^{[12
]}

Dreyling, Martin ^{[13
]}

Hagenbeek, Anton ^{[14
]}

Zinzani, Pier Luigi ^{[15
]}

Yalamanchili, Sreeni ^{[16
]}

Lu, Dan ^{[16
]}

Jones, Cheryl ^{[16
]}

Jones, Surai ^{[16
]}

Chu, Yu-Waye ^{[16
]}

Sharman, Jeff P. ^{[17
]}

机构：

[1] Ctr Hosp Reg Univ Lille, Lille, France

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[4] NYU, Sch Med, New York, NY USA

[5] Northwest Canc Specialists, Vancouver, WA USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] Ctr Lymphoid Canc, Vancouver, BC, Canada

[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[9] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[10] Ctr Henri Becquerel, F-76038 Rouen, France

[11] Georgetown Univ Hosp, Washington, DC 20007 USA

[12] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[13] Klinikum Univ Munchen Campus Grosshadern, Munich, Germany

[14] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[15] Univ Bologna, Bologna, Italy

[16] Genentech Inc, San Francisco, CA USA

[17] Willamette Valley Canc Inst US Oncol Res, Springfield, OR USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Randomized Phase 2 Trial of Polatuzumab Vedotin With Bendamustine and Rituximab in Relapsed/Refractory FL and DLBCL
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 14 - 16
[22] Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Advani, Ranjana H.
Lebovic, Daniel
Chen, Andy
Brunvand, Mark
Goy, Andre
Chang, Julie E.
Hochberg, Ephraim
Yalamanchili, Sreeni
Kahn, Robert
Lu, Dan
Agarwal, Priya
Dere, Randall C.
Hsieh, Hsin-Ju
Jones, Surai
Chu, Yu-Waye
Cheson, Bruce D.
CLINICAL CANCER RESEARCH, 2017, 23 (05) : 1167 - 1176
[23] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Hirata, Jamie
Perretti, Thomas
Musick, Lisa
McMillan, Andrew K.
BLOOD, 2021, 138
[24] Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
Kinoshita, Tomohiro
Hatake, Kiyohiko
Yamamoto, Kazuhito
Higuchi, Yusuke
Murakami, Satsuki
Terui, Yasuhito
Yokoyama, Masahiro
Maruyama, Dai
Makita, Shinichi
Hida, Yukari
Saito, Tomohisa
Tobinai, Kensei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (01) : 70 - 77
[25] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
Matasar, M.
Herrera, A. F.
Kamdar, M.
Mehta, A.
Assouline, S.
Fleury, I.
Kim, T. M.
Kim, W. S.
Bosch, F.
Radford, J.
Flowers, C. R.
Bu, L.
Hong, W. -J.
Sehn, L. H.
HAEMATOLOGICA, 2017, 102 : 173 - 173
[26] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
Song, Yuqin
Zhang, Qingyuan
Cai, Qingqing
Song, Yongping
Zhang, Liling
He, Pengcheng
Wang, Li
Hirata, Jamie
Musick, Lisa
Deng, Rong
Liu, Wenxin
Wang, Xin
Zhu, Jun
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07)
[27] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Gritti, Giuseppe
Marlton, Paula
Phillips, Tycel J.
Arthur, Christopher
Bannerji, Rajat
Corradini, Paolo
Johnston, Anna
Seymour, John F.
Yuen, Sam
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Flowers, Christopher
BLOOD, 2020, 136
[28] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB (POLA plus BR) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): UPDATED RESULTS OF A PHASE IB/II RANDOMIZED STUDY AND PRELIMINARY RESULTS OF A SINGLE ARM EXTENSION
Pinto, A.
Sehn, L. H.
Hertzberg, M.
Opat, S.
Herrera, A. F.
Assouline, S.
Flowers, C. R.
Kim, T. M.
McMillan, A.
Ozcan, M.
Safar, V.
Salles, G.
Musick, L.
Hirata, J.
Chang, Y. M.
Ku, G.
Matasar, M. J.
HAEMATOLOGICA, 2021, 106 (10) : 69 - 69
[29] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
Vodicka, Prokop
Benesova, Katerina
Janikova, Andrea
Prochazka, Vit
Belada, David
Mocikova, Heidi
Steinerova, Katerina
Duras, Juraj
Karban, Josef
Hanackova, Veronika
Sykorova, Alice
Obr, Ales
Trneny, Marek
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
[30] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
Kambhampati, Swetha
Mei, Matthew
Chen, Lu
Puverel, Sandrine
Chen, Robert
Popplewell, Leslie L.
Nikolaenko, Liana
Peters, Lacolle
Armenian, Saro H.
Kwak, Larry W.
Rosen, Steve T.
Forman, Stephen J.
Herrera, Alex F.
BLOOD, 2022, 140 : 9418 - 9419

← 1 2 3 4 5 →